Trial Profile

Phase II Trial of TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 09 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tisagenlecleucel (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
Focus Therapeutic Use
Acronyms TIGER-CTL019

Most Recent Events

06 Mar 2023 Status changed from active, no longer recruiting to discontinued.
02 Mar 2022 Status changed from recruiting to active, no longer recruiting.
11 Jun 2021 Planned End Date changed from 1 Jul 2024 to 1 Sep 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com